Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly.

Saavedra D, Fuertes SA, Suárez GM, González A, Lorenzo-Luaces P, García B, Aznar E, Mazorra Z, Crombet T, Speiser DE, Lage A.

Exp Gerontol. 2019 Sep;124:110633. doi: 10.1016/j.exger.2019.110633. Epub 2019 Jun 14.

PMID:
31207285
2.

Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer.

Sanchez L, Muchene L, Lorenzo-Luaces P, Viada C, Rodriguez PC, Alfonso S, Crombet T, Neninger E, Shkedy Z, Lage A.

Semin Oncol. 2018 Jan;45(1-2):52-57. doi: 10.1053/j.seminoncol.2018.04.005. Epub 2018 May 1.

PMID:
30318084
3.

CIMAvax-EGF: Toward long-term survival of advanced NSCLC.

Saavedra D, Neninger E, Rodriguez C, Viada C, Mazorra Z, Lage A, Crombet T.

Semin Oncol. 2018 Jan;45(1-2):34-40. doi: 10.1053/j.seminoncol.2018.04.009. Epub 2018 May 1. Review.

4.

Nimotuzumab: beyond the EGFR signaling cascade inhibition.

Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T.

Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Review.

5.

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.

Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, Hechavarría E, González Z, González A, Lugiollo M, Cuevas I, Frómeta C, Mestre BF, Barroso MC, Crombet T, Ferris RL.

Front Pharmacol. 2017 Jun 19;8:382. doi: 10.3389/fphar.2017.00382. eCollection 2017.

6.

Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.

Valdes-Zayas A, Gonzalez Z, Mulens V, Vega AM, Perez K, Lorenzo-Luaces P, Rubio MC, Estevez A, Curbelo I, Fernandez LE, Crombet T, Mazorra Z.

J Immunother. 2017 Oct;40(8):289-301. doi: 10.1097/CJI.0000000000000175.

PMID:
28604556
7.

Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.

Caballero I, Aira LE, Lavastida A, Popa X, Rivero J, González J, Mesa M, González N, Coba K, Lorenzo-Luaces P, Wilkinson B, Santiesteban Y, Santiesteban Y, Troche M, Suarez E, Crombet T, Sánchez B, Casacó A, Macías A, Mazorra Z.

Front Pharmacol. 2017 May 10;8:263. doi: 10.3389/fphar.2017.00263. eCollection 2017.

8.

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.

Saavedra D, Crombet T.

Front Immunol. 2017 Mar 13;8:269. doi: 10.3389/fimmu.2017.00269. eCollection 2017. Review.

9.

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.

Rodriguez PC, Popa X, Martínez O, Mendoza S, Santiesteban E, Crespo T, Amador RM, Fleytas R, Acosta SC, Otero Y, Romero GN, de la Torre A, Cala M, Arzuaga L, Vello L, Reyes D, Futiel N, Sabates T, Catala M, Flores YI, Garcia B, Viada C, Lorenzo-Luaces P, Marrero MA, Alonso L, Parra J, Aguilera N, Pomares Y, Sierra P, Rodríguez G, Mazorra Z, Lage A, Crombet T, Neninger E.

Clin Cancer Res. 2016 Aug 1;22(15):3782-90. doi: 10.1158/1078-0432.CCR-15-0855. Epub 2016 Feb 29.

10.

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients.

Saavedra D, García B, Lorenzo-Luaces P, González A, Popa X, Fuentes KP, Mazorra Z, Crombet T, Neninger E, Lage A.

Cancer Immunol Immunother. 2016 Jan;65(1):37-45. doi: 10.1007/s00262-015-1773-6. Epub 2015 Nov 20.

PMID:
26589409
11.

Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer.

Quián YP, Crombet T, Batista JF, Prats A, Perera A.

Clin Nucl Med. 2016 Mar;41(3):244-6. doi: 10.1097/RLU.0000000000001011.

PMID:
26447381
12.

A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.

Cetina L, Crombet T, Jiménez-Lima R, Zapata S, Ramos M, Avila S, Coronel J, Charco E, Bojalil R, Astudillo H, Bazán B, Dueñas-González A.

Cancer Biol Ther. 2015;16(5):684-9. doi: 10.1080/15384047.2015.1026483.

13.

Is there a subgroup of long-term evolution among patients with advanced lung cancer?: hints from the analysis of survival curves from cancer registry data.

Sanchez L, Lorenzo-Luaces P, Viada C, Galan Y, Ballesteros J, Crombet T, Lage A.

BMC Cancer. 2014 Dec 11;14:933. doi: 10.1186/1471-2407-14-933.

14.

A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.

Alfonso S, Valdés-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernández M, Viada CE, Mendoza IC, Guerra PP, García E, Ortiz RA, de la Torre AV, Cepeda M, Pérez K, Chong E, Hernández AM, Toledo D, González Z, Mazorra Z, Crombet T, Pérez R, Vázquez AM, Macías AE.

Clin Cancer Res. 2014 Jul 15;20(14):3660-71. doi: 10.1158/1078-0432.CCR-13-1674. Epub 2014 May 1.

15.

Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Solomon MT, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J, Lorenzo-Luaces P, Crombet T.

Cancer Biol Ther. 2014 May;15(5):504-9. doi: 10.4161/cbt.28021. Epub 2014 Feb 12.

16.

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.

Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, Catalá M, Griego MG, Martell JA, Luaces PL, Ballesteros J, de-Castro N, Bach F, Crombet T.

BMC Cancer. 2013 Jun 19;13:299. doi: 10.1186/1471-2407-13-299.

17.

A view on EGFR-targeted therapies from the oncogene-addiction perspective.

Perez R, Crombet T, de Leon J, Moreno E.

Front Pharmacol. 2013 Apr 26;4:53. doi: 10.3389/fphar.2013.00053. eCollection 2013.

18.

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.

Rodriguez PC, Neninger E, García B, Popa X, Viada C, Luaces P, González G, Lage A, Montero E, Crombet T.

J Immune Based Ther Vaccines. 2011 Oct 24;9:7. doi: 10.1186/1476-8518-9-7.

19.

Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease.

Rodriguez G, Gonzalez G, Crombet T, Lage A.

Expert Rev Respir Med. 2011 Jun;5(3):337-42. doi: 10.1586/ers.11.12. Review.

PMID:
21702656
20.

Control of advanced cancer: the road to chronicity.

Lage A, Crombet T.

Int J Environ Res Public Health. 2011 Mar;8(3):683-97. doi: 10.3390/ijerph8030683. Epub 2011 Mar 1. Review.

21.

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects.

Perez R, Moreno E, Garrido G, Crombet T.

Cancers (Basel). 2011 Apr 18;3(2):2014-31. doi: 10.3390/cancers3022014.

22.

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.

Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R.

Cancer Biol Ther. 2011 Feb 15;11(4):373-82. Epub 2011 Feb 15.

PMID:
21150278
23.

Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment.

Gonzalez G, Crombet T, Lage A.

Curr Cancer Drug Targets. 2011 Jan;11(1):103-10. Review.

PMID:
21062240
24.

Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.

Mulens V, de la Torre A, Marinello P, Rodríguez R, Cardoso J, Díaz R, O'Farrill M, Macias A, Viada C, Saurez G, Carr A, Crombet T, Mazorra Z, Perez R, Fernandez LE.

Hum Vaccin. 2010 Sep 14;6(9). doi: 10.4161.hv.6.9.12571. Epub 2010 Sep 14.

PMID:
20855939
25.

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.

Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T.

Cancer Biol Ther. 2010 Mar 1;9(5):343-9. Epub 2010 Mar 20.

PMID:
20448462
26.

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J.

Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6.

27.

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS.

MAbs. 2009 Jan-Feb;1(1):41-8. Review.

28.

Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.

Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, Mazorra Z, Fleites G, González M, Wilkinson B, González G, Lage A.

J Immunother. 2009 Jan;32(1):92-9. doi: 10.1097/CJI.0b013e31818fe167.

PMID:
19307998
29.

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.

García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T.

Clin Cancer Res. 2008 Feb 1;14(3):840-6. doi: 10.1158/1078-0432.CCR-07-1050.

30.

Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.

Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, Viña L, Orphee R, Hernández O, González C, Fuentes D, Rodríguez V, Charro L, Baro F, Macías A, Pérez A, Morales Y, Subirós N, González B, Ramos M, Rodriquez L, Ballester-Labrada A, Crombet T.

Cancer Biol Ther. 2007 Sep;6(9):1390-5. Epub 2007 Jun 5.

PMID:
17827980
31.

Systematization of the vesical and uterovaginal efferences of the female inferior hypogastric plexus (pelvic): applications to pelvic surgery on women patients.

Mauroy B, Bizet B, Bonnal JL, Crombet T, Duburcq T, Hurt C.

Surg Radiol Anat. 2007 Apr;29(3):209-17. Epub 2007 Mar 13.

PMID:
17406966
32.

Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials.

González G, Crombet T, Neninger E, Viada C, Lage A.

Hum Vaccin. 2007 Jan-Feb;3(1):8-13. Epub 2007 Jan 22.

PMID:
17204867
33.

Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.

Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, Neninger E, Pérez M, Sánchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N.

Nucl Med Commun. 2005 Dec;26(12):1049-57.

PMID:
16264350
34.

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A.

J Clin Oncol. 2004 May 1;22(9):1646-54.

PMID:
15117987
35.

Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody.

Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Becquer MA, Fernández-Sánchez E.

Eur J Pharm Sci. 2004 Feb;21(2-3):261-70.

PMID:
14757498
36.

Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.

Lage A, Crombet T, González G.

Ann Med. 2003;35(5):327-36. Review.

PMID:
12952019
37.

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.

Crombet T, Torres L, Neninger E, Catalá M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R, Lage A.

J Immunother. 2003 Mar-Apr;26(2):139-48.

PMID:
12616105
38.

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.

Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, Neninger E, Garcia B, Mulet A, Perez R, Lage R.

Ann Oncol. 2003 Mar;14(3):461-6.

PMID:
12598354
39.

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS.

Cancer Res. 2001 Jul 1;61(13):5090-101.

40.

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.

Crombet T, Torres O, Rodríguez V, Menéndez A, Stevenson A, Ramos M, Torres F, Figueredo R, Veitía I, Iznaga N, Pérez R, Lage A.

Hybridoma. 2001 Apr;20(2):131-6.

PMID:
11394532
41.

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.

Crombet T, Torres O, Neninger E, Catalá M, Rodríguez N, Ramos M, Fernández E, Iznaga N, Pérez R, Lage A.

Cancer Biother Radiopharm. 2001 Feb;16(1):93-102.

PMID:
11279803
42.

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.

González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y, Marinello P, Guillén G, Lage A.

Ann Oncol. 1998 Apr;9(4):431-5.

PMID:
9636835

Supplemental Content

Loading ...
Support Center